genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.
Frequently asked questions
What sector does Genoway (ALGEN) operate in?
Genoway belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Genoway (ALGEN) current stock price?
As of the latest data, Genoway stock price is €2.48, with a previous close of €2.52. Genoway lost -€0.04 in the last trading session, representing a -1.59% loss.
What is Genoway (ALGEN) current market capitalization?
Genoway market cap is approximately 30.60 million.
What is Genoway (ALGEN) Earnings Per Share (EPS)?
The trailing EPS is €0.10.
What is Genoway (ALGEN) Price-to-Earnings (P/E) ratio?
Genoway current P/E ratio is 24.8.
Does Genoway (ALGEN) pay dividends?
No. Genoway does not pay a dividend.
What is Genoway (ALGEN) beta (volatility) score?
Genoway has a beta of 0.366, indicating lower volatility than the overall market.
